C60 fullerene derivatized nanoparticles and their application to therapeutics

Recent Patents on Nanotechnology

Volumn 6, Issue 2, 2012, Pages 105-113

  Lin, Chun Mao ^a,b   Lu, Tan Yi ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antioxidant; Apoptosis; Autophagy; Blood brain barrier (BBB); Cytotoxicity; Fullerene; Fullerene dyad; Fulleropyrrolidine xanthine dyad; Graphene; Nanomedicine; Nanoparticle; Nanotechnology; Neurodegenerative disease; Neuroprotective

Indexed keywords

ANTIOXIDANTS; BLOOD; CELL DEATH; CHEMICAL MODIFICATION; CYTOTOXICITY; DISEASES; GRAPHENE; MEDICAL APPLICATIONS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; NANOSTRUCTURES; NANOTECHNOLOGY; NEURODEGENERATIVE DISEASES; VIRUSES;

AUTOPHAGY; BLOOD-BRAIN BARRIER; FULLERENE DYADS; FULLEROPYRROLIDINES; NEUROPROTECTIVE;

FULLERENES;

ANTIVIRUS AGENT; DRUG; DRUG CARRIER; FULLERENE C60; FULLERENE DERIVATIVE; NANOPARTICLE;

ARTICLE; BLOOD BRAIN BARRIER; CHEMISTRY; DEGENERATIVE DISEASE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; NANOMEDICINE; NANOTECHNOLOGY; PHOTOCHEMOTHERAPY;

ANTIVIRAL AGENTS; BLOOD-BRAIN BARRIER; DRUG CARRIERS; FULLERENES; HIV INFECTIONS; HUMANS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; NEURODEGENERATIVE DISEASES; PHARMACEUTICAL PREPARATIONS; PHOTOCHEMOTHERAPY;

EID: 84860506366     PISSN: 18722105     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221012800270135     Document Type: Article

References (86)

1. Geckeler KE, Samal S. Featured Article Syntheses and Properties of Macromolecular Fullerenes, A Review. Polym Int 1999; 48: 743-747.
2. Kroto HW, Heath JR, O'Brien SC, Curl RF, Smalley RF. C60: Buckminsterfullerene. Nature 1985; 318:162-163.
3. Nobel Foundation Announcement. Available at: http://www.nobelprize.org/nobel_prizes/physics/laureates/2010/(Accessed on: February 23, 2012)
4. Geim AK, Novoselov KS. The Rise of Graphene. Nat Mater 2007; 6: 183-191.
5. Feng L, Liu Z. Graphene in Biomedicine: Opportunities and Challenges. Nanomedicine (Lond). 2011; 6: 317-324.
6. Qiao R, Roberts AP, Mount AS, Klaine SJ, Ke PC. Translocation of C60 and Its Derivatives Across a Lipid Bilayer. Nano Lett 2007; 7: 614-619.
7. Aldersey-Williams H. The Most Beautiful Molecule: the Discovery of Buckyball. New York: John Wiley, 1995.
8. Geckeler KE. Macromolecular Fullerene Chemistry. Trends Polym Sci 1994; 2: 355.
9. Suzuki T, Li Q, Khemani KC, Wudl F. Dihydrofulleroid H3C61: Synthesis and Properties of the Parent Fulleroid. J Am Chem Soc 1992; 14: 7301-7302.
10. Liu B, Bunker CE, Sun YJ. Preparation and Characterization of Soluble Pendant [60]Fullerene-Polystyrene Polymers. Chem Commun 1996; 10: 1241-1242.
11. Geckeler KE, Hirsch A. Polymer-Bound C60. J Am Chem Soc 1993; 115: 3850-3851.
12. Patil AO, Schriver GW, Carstensen B, Lundberg RD. Fullerene Functionalized Polymers. Polym Bull 1993; 30: 187-190.
13. Bezmel'nitsyn VN, Eletskii AV, Okun' MV. Fullerenes in Solutions. Physics-Uspekhi 1998; 41: 1091-1114.
14. Ruoff RS, Tse DS, Malhotra R, Lorents DC. Solubility of Fullerene (C60) in a Variety of Solvents. J Phys Chem 1993; 97: 3379-3383.
15. Sun YP, Liu B, Morton DK. Preparation and Characterization of a Highly Water-Soluble Pendant Fullerene Polymer. Chem Commun 1996; 24: 2699-2700.
16. Moussa F, Trivin F, Céolin R, et al. Early Effects of C60- Administration in Swiss Mice: A Preliminary Account for in vivo C60 Toxicity. Fullerene Sci Technol 1996; 4: 21-29.
17. Moussa F, Pressac M, Hadehouel M, et al. C60 Fullerene Toxicity: Preliminary Account of an in vivo Study. In: Pennington NJ, Kadish K, Ruoff R, (eds.) Fullerenes. Proc Electrochem Soc 1997; 5: 32-36.
18. Mori T, Takada H, Ito S, Matsubayashi K, Miwa N, Sawaguchi T. Preclinical Studies on Safety of Fullerene upon Acute Oral Administration and Evaluation for No Mutagenesis. Toxicology 2006; 225: 48-54.
19. Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F. [60]Fullerene is a Powerful Antioxidant in vivo with no Acute or Subacute Toxicity. Nano Lett 2005; 5: 2578-2585.
20. Kolosnjaj J, Szwarc H, Moussa F. Toxicity Studies of Fullerenes and Derivatives. In Chan WC. Bioappl Nanopart. Landes Biosci 2007a; 168-180.
21. Kolosnjaj J, Szwarc H, Moussa F. Toxicity Studies of Carbon Nanotubes. Adv Exp Med Biol 2007b; 620: 181-204.
22. Nakamura E, Isobe H. Functionalized Fullerene in Water: The First 10 Years of Their Chemistry, Biology, and Nanoscience. Acc Chem Res 2003; 36: 807-815.
23. Fletcher JS, Conlan XA, Jones EA, Biddulph G, Lockyer NP, Vickerman JC. TOF-SIMS Analysis Using C60 Effect of Impact Energy on Yield and Damage. Ana Chem 2006; 78: 1827-1831.
24. Rainer MV, Szabo Z, Bachmann S, et al. Development and Application of C60-Fullerene Bound Silica for Solid-Phase Extraction of Biomolecules. Anal Chem 2007; 79: 8144-8153.
25. Hizume Y, Tashiro K, Charvet R, et al. Chiroselective Assembly of a Chiral Porphyrin-Fullerene Dyad: Photoconductive Nanofiber with a Top-Class Ambipolar Charge-Carrier Mobility. J Am Chem Soc 2010; 132: 6628-6629.
26. Nishizawa T, Lim HK, Tajima K, Hashimoto K. Efficient Dyad- Based Organic Solar Cells with a Highly Crystalline Donor Group. Chem Commun 2009; 18: 2469-24671.
27. Edwin LC. Nanomedicine: An International Glimpse. J Exp Clin Med 2011; 3:1-3.
28. Sharma R, Kwon S, Baktur R, Sharma A. Nanotoxicity Assessment Toward the Applications of Carbon Nanotubes as a Small Biomolecule Carrier in Drug Delivery System. NSTI-Nanotech 2009; 2: 150-153.
29. Kirpatrick L. Carbon Nanotube Compositions Complexed with Multiple Bioactive Agents and Methods Related Thereto. CA2762524 A1, 2011.
30. Li Q, Xiu Y, Zhang X, et al. Biodistribution of Fullerene Derivative C60(OH)x(O)y. Chi Sci Bull 2001; 46: 1615-1617.
31. Chiang LY, Lai YL, Tsai MC, et al. Therapeutic use of water-soluble fullerene derivatives. US5994410 (A), 1999.
32. Tsuchiya T, Yamakoshi YN, Miyata N. A Novel Promoting Action of Fullerene C60 on the Chondrogenesis in Rat Embryonic Limb Bud Cell Culture System. Biochem Biophys Res Commun 1995; 206: 885-894.
33. Dugan LL, Turetsky DM, Du C, et al. Carboxyfullerenes as Neuroprotective Agents. Proc Nat Acad Sci USA 1997; 94: 9434-9439.
34. Yamago S, Tokuyama H, Nakamura E, et al. In vivo Biological Behavior of a Water-Miscible Fullerene: 14C Labeling, Absorption, Distribution, Excretion and Acute Toxicity. Chem Biol 1995; 2: 385-389.
35. Satoh M, Matsuo K, Kiriya H, et al. Inhibitory Effects of a Fullerene Derivative, Dimalonic Acid C60, on Nitric Oxide-Induced Relaxation of Rabbit Aorta. Eur J Pharmacol 1997; 327: 175-181.
36. Tykhomyrov AA, Nedzvetsky VS, Klochkov VK, Andrievsky GV. Nanostructures of Hydrated C60 Fullerene (C60HyFn) Protect Rat Brain Against Alcohol Impact and Attenuate Behavioral Impairments of Alcoholized Animals. Toxicol 2008; 246: 158-165.
37. Chung BH, Jeong JY. Water-Soluble Fluorescent Fullerene Derivatives and Method for Preparing the Same. KR20110120224 A, 2011.
38. Tong J, Zimmerman MC, Li S, et al. Neuronal Uptake and Intracellular Superoxide Scavenging of a Fullerene (C60)-Poly(2-Oxazoline)s Nanoformulation. Biomaterials. 2011; 32: 3654-3665.
39. Rasnetsov LD, Shvartsam IY, Lyalina IK, Rasnetsova BE. Agent for Inhibiting Membrane Virus Reproduction, Method for the Production Thereof, Pharmaceutical Composition and Method for Inhibiting Viral Infections. US2006122276 A1, 2006.
40. Sagman U. Application and Commercial Prospects of Fullerenes in Medicine and Biology Perspectives of Fullerene Nanotechnology. UK: Kluwer Academic, 2002; (Pt 4):145-153.
41. Hughes GA. Nanostructure-Mediated Drug Delivery. Nanomedicine 2005; 1: 22-30.
42. Martin CR, Kohli P. The Emerging Field of Nanotube Biotechnology. Nat Rev Drug Discov 2003; 2: 29-37.
43. Drummond DC, Meyer O, Hong K, Kirpotin DB. Papahadjopoulos D. Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors. Pharmacol Rev 1999; 51: 691-743.
44. Tegos GP, Demidova TN, Arcila-Lopez D, et al. Cationic Fullerenes are Effective and Selective Antimicrobial Photosensitizers. Chem Biol 2005; 12: 1127-1135.
45. Feuerstein I, Najam-ul-Haq M, Rainer M, et al. A. Material-Enhanced Laser Desorption/Ionization (MELDI)-a New Protein Profiling Tool Utilizing Specific Carrier Materials for Time of Flight Mass Spectrometric Analysis. J Am Soc Mass Spectrom 2006; 17: 1203-1208.
46. Rainer M, Muhammad NU, Huck CW, et al. Ultra-Fast Mass Fingerprinting by High-Affinity Capture of Peptides and Proteins on Derivatized Poly(Glycidyl Methacrylate/ Divinylbenzene) for the Analysis of Serum and Cell Lysates. Rapid Commun Mass Spectrom 2006; 20: 2954-2960.
47. Bakry R, Rainer MV, Najam-ul-Haq M, et al. Medicinal Applications of Fullerenes. Int J Nanomed 2007; 2: 639-649.
48. Sitharaman B, Zakharian TY, Saraf A, et al. Water-Soluble Fullerene (C60) Derivatives as Nonviral Gene-Delivery Vectors. Mol Pharm 2008; 5: 567-578.
49. Wong-Ekkabut J, Baoukina S, Triampo W, Tang IM, Tieleman DP, Monticelli L. Computer Simulation Study of Fullerene Translocation Through Lipid Membranes. Nat Nanotechnol 2008; 3: 363-368.
50. Gause C. Fullerene Nanomedicines for Medical and Healthcare Application. Available at: http://www.hhmglobal.com/knowledgebank/articles/fullerene-nanomedicines-for-medical-and-healthcareapplications. (Accessed on: May 30, 2011).
51. Lin AM, Chyi BY, Wang SD, et al. Carboxyfullerene Prevents Iron-Induced Oxidative Stress in Rat Brain. J Neurochem 1999; 72: 1634-1640.
52. Lin AM, Fang SF, Lin SZ, Chou CK, Luh TY, Ho LT. Local Carboxyfullerene Protects Cortical Infarction in Rat Brain. Neurosci Res 2002; 43: 317-321.
53. Chen YW, Hwang KC, Yen CC, Lai YL. Fullerene Derivatives Protect Against Oxidative Stress in RAW 264.7 Cells and Ischemia-Reperfused Lungs. Am J Physiol Regul Integr Comp Physiol 2004; 287: 21-26.
54. Bisaglia M, Natalini B, Pellicciari R, et al. C3-Fullero-Trismethanodicarboxylic Acid Protects Cerebellar Granule Cells from Apoptosis. J Neurochem 2000; 74: 1197-1204.
55. Huang YL, Shen CK, Luh TY, Yang HC, Hwang KC, Chou CK. Blockage of Apoptotic Signaling of Transforming Growth Factor-Beta in Human Hepatoma Cells by Carboxyfullerene. Eur J Biochem 1998; 254: 38-43.
56. Straface E, Natalini B, Monti D, et al. C3-Fullero-Tris-Methanodicarboxylic Acid Protects Epithelial Cells from Radiation-Induced Anoikia by Influencing Cell Adhesion Ability. FEBS Lett 1999; 454: 335-340.
57. Modi G, Pillay V, Choonara YE, Ndesendo VMK, du Toit LC, Naidoo D. Nanotechnological Applications for the Treatment of Neurodegenerative Disorders Progress in Neurobiology. Prog Neurobiol 2009; 88: 272-285.
58. Pardridge WM. The Blood-Brain Barrier: Bottleneck in Brain Drug Development. Neuro Rx 2005; 2: 3-14.
59. Kabanov AV, Gendelman HE. Nanomedicine in the Diagnosis and Therapy of Neurodegenerative Disorders. Prog Polym Sci 2007; 32: 1054-1082.
60. Kreuter J, Shamenkov D, Petrov V, Ramge P, Koch-Brandt C. Apolipoprotein-Mediated Transport of Nanoparticle-Bound Drugs Across the Blood-Brain Barrier. J Drug Target 2002; 10: 317-325.
61. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the Duration of the Anticonvulsive Activity of a Novel NMDA Receptor Antagonist Using Poly(-Butylcyanoacrylate) Nanoparticles as a Parenteral Controlled Release System. Eur J Pharm Biopharm 2000; 49: 103-109.
62. Lao F, Chen L, Li W, et al. Fullerene Nanoparticles Selectively Enter Oxidation-Damaged Cerebral Microvessel Endothelial Cells and Inhibit JNK-Related Apoptosis. J Am Chem Soc 2009; 3: 3358-3368.
63. Da Ros T, Spalluto G, Prato M. Biological Applications of Fullerene Derivatives: A Brief Overview. Croat Chem Acta 2001; 74: 743-755.
64. Rancan F, Rosan S, Boehm F, et al. Cytotoxicity and Photocytotoxicity of a Dendritic C60 Mono-Adduct and a Malonic Acid C60 Tris-Adduct on Jurkat Cells. J Photochem Photobiol 2002; 67: 157-162.
65. Mroz P, Pawlak A, Satti M, et al. Functionalized Fullerenes Mediate Photodynamic Killing of Cancer Cells: Type I Versus Type II Photochemical Mechanism. Free Radic Biol Med 2007; 43: 711-719.
66. Friedman SH, DeCamp DL, Sijbesma RP, Srdanov G, Wudl F, Kenyon GL. Inhibition of the HIV-1 Protease by Fullerene Derivatives: Model Building Studies and Experimental Verification. J Am Chem Soc 1993; 115: 6506-6509.
67. Sijbesma R, Srdanov G, Wudl F, et al. Synthesis of a Fullerene Derivative for The Inhibition of HIV Enzymes. J Am Chem Soc 1993; 115: 6510-6512.
68. Kotelnikova RA, Bogdanov GN, Frog EC, et al. Nanobionics of Pharmacologically Active Derivatives of Fullerene C60. J Nanopart Res 2003; 5: 561-566.
69. Mashino T, Shimotohno K, Ikegami N, et al. Human Immunodeficiency Virus-Reverse Transcriptase Inhibition and Hepatitis C Virus RNA-Dependent RNA Polymerase Inhibition Activities of Fullerene Derivatives. Bioorg Med Chem Lett 2005; 15: 1107-1109.
70. Dugan LL, Behrens MM, Ali SS. Compositions and Methods for Ameliorating CNS Inflammation, Psychosis, Delirium, PTSD, or PTSS. US2010297070 A1, 2010.
71. Calvo P, Gouritin B, Chacun H, et al. Long-Circulating Pegylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery. Pharm Res 2001; 18: 1157-1166.
72. Alyaudtin RN, Reichel A, Lobenberg R, Ramgel P, Kreuter J, Begley DJ. Interaction of Poly(Butylcyanoacrylate) Nanoparticles with the Blood-Brain Barrier In Vivo and In Vitro. J Drug Target 2001; 9: 209-221.
73. Kreuter J, Ramge P, Petrov V, et al. Direct Evidence that Polysorbate- 80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS Via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles. Pharm Res 2003; 20: 409-416.
74. Steiniger SC, Kreuter J, Khalansky AS, et al. Chemotherapy of Glioblastoma in Rats Using Doxorubicin-Loaded Nanoparticles. Int J Cancer 2004; 109: 759-767.
75. Vinogradov SV, Zeman AD, Batrakova EV, Kabanov AV. Polyplex Nanogel Formulations for Drug Delivery of Cytotoxic Nucleoside Analogs. J Control Release 2005; 107: 143-157.
76. Nguyen HK, Lemieux P, Vinogradov SV, et al. Evaluation of Polyetherpolyethyleneimine Graft Copolymers as Gene Transfer Agents. Gene Ther 2000; 7: 126-138.
77. Harada-Shiba M, Yamauchi K, Harada A, Takamisawa I, Shimokado K, Kataoka K. Polyion Complex Micelles as Vectors in Gene Therapy-Pharmacokinetics and In Vivo Gene Transfer. Gene Ther 2002; 9: 407-414.
78. Oishi M, Hayashi H, Iijima M, Nagasaki Y. Endosomal Release and Intracellular Delivery of Anticancer Drugs Using Ph-Sensitive Pegylated Nanogels. J Mater Chem 2007; 17: 3720-3725.
79. Michael G, Howard LW, Alon M, Amnon BS, Yoni E, Dan F. Novel Neuroprotective Compounds and Uses Thereof. US2010144868 A1, 2010.
80. Huang ST, Ho CS, Lin CM, Fang HW, Peng YX. Development and Biological Evaluation of C(60) Fulleropyrrolidine-Thalidomide Dyad as a New Anti-Inflammation Agent. Bioorg Med Chem 2008a; 16: 8619-8626.
81. Huang ST, Liao JS, Fang HW, Lin CM. Synthesis and Anti- Inflammation Evaluation of New C60 Fulleropyrrolidines Bearing Biologically Active Xanthine. Bioorg Med Chem Lett 2008b; 18: 99-103.
82. Lu TY, Kao PF, Lee CM, Huang ST, Lin CM. C60 Fullerene Nanoparticle Prevents the β-Amyloid Peptide Induced Cytotoxicity in Neuro 2A Cells. J Food Drug Anal 2011; 19: 151-158.
83. Lee CM, Huang ST, Huang SH, et al. C60 Fullerene-Pentoxifylline Dyad Nanoparticles Enhance Autophagy to Avoid Cytotoxic Effects Caused by the β-Amyloid Peptide. Nanomedicine-Nanotechnol 2011; 7: 107-114.
84. Kepley CL, Lenk RP, Macfarland D. Fullerene Therapies for Inflammation and Inhibition of Build-Up of Arterial Plaque. US 2011251158 A1, 2011.
85. Petrik VI. Compositions and methods for medical use of graphenecontaining compositions. US2006134096 A1, 2006.
86. Paul W, Sharma CP. Blood Compatibility and Biomedical Applications of Graphene. Trends Biomater Artif Organs 2011; 25: 91-94.